top of page

Pipeline

Bureau met Stethoscoop

  UPyTher leverages its proprietary hydrogel-drug formulation platform

  to create a pipeline of specialty-products for peritoneal oncology

PERITONEAL ONCOLOGY

Discovery

Nonclinical

Clinical

Status

UPT-211

PoC & PK in two species.

Nonclinical toxicity studies are underway to facilitate a FiH trial in 2026.

peritoneal carcinomatosis from

Colorectal Cancer

UPT-122

peritoneal carcinomatosis from

Ovarian Cancer

PoC has been established in rodent models

PERITONEAL IMMUNO-ONCOLOGY

Discovery

Nonclinical

Clinical

Status

NON-DISCLOSED

peritoneal carcinomatosis from

Colorectal Cancer

UPyTher is evaluating immunomodulatory drugs for  intraperitoneal immunotherapy

bottom of page